Description: This article summarizes insights from a 2021 survey of more than 40 life insurance companies with a focus on trends in reinsurand and in-force management. While reinsurance objectives and methods have remained steadfast in a sea of economic and regulatory impacts, life companies still are looking at different solutions to make improvements in profitability, stability, and scale.

Description: Read the May 2020 issue of Reinsurance News published by the Reinsurance Section. Newsletters provide practical information for the working actuary, articles on trends that impact sections and news about section activities.

Description: Summary of ReFocus 2019

Description: This articles discusses the results of a first quarter 2019 online survey sponsored by the Reinsurance Section Council.

Description: Managed care networks are important to control rising health care costs . these need to be priced appropriately to produce the right results for all stakeholders . This includes analysis of utilization and costs for both in and out of network claims . A variety of risk and administrative service options exist for entities assuming such risk .

Description: Heart disease, critical illness insurance and the path to change – a personal essay by Jing Lang, FSA, FCIA, FLMI.

Description: This article discusses the impact of consolidation in the U.S. life reinsurance

Description: Describes the changes in insurance regulation on both an international and US perspective.

Description: Re/insurance rates have been increasing since 2018, although pricing momentum has decelerated recently. Insurers and reinsurers are working to enhance profitability and improve the value proposition for clients in an environment of uncertainty about natural catastrophes, COVID-19-related losses, and social inflation, among other factors. This article describes drivers of the current underwriting cycle, compares it with past cycles, and provides considerations for the future.

Description: Cell and Gene Therapy (CGT) are life-changing treatments where conditions such as cancer, hemophilia, spinal muscular atrophy and blindness are being cured. These are great for individuals and society, but the treatment costs are expensive which is bad for payers and reinsurers. This article explores ways for health reinsurance actuaries to participate in the space and evaluate the risk associated with these treatments